2026 IAP Meeting and Dinner
Iowa Association of Pathologists Biennial Meeting
Friday, May 15, 2026 | 5:00 – 9:00 PM
The Graduate Hotel | Iowa City, Iowa
Join Us for an Evening of Connection and Collaboration
Pathologists from across Iowa will gather for an evening of networking, education, and professional growth. The 2026 Biennial Meeting will bring together leaders in pathology and laboratory medicine to discuss emerging trends, share expertise, and strengthen our statewide community.
This is your opportunity to connect with colleagues, learn from distinguished speakers, and help shape the future of pathology in Iowa.
Event Highlights
-
Engaging educational programming led by Iowa’s top pathologists and guest speakers
-
Networking reception with hosted appetizers and beverages
-
Association updates and recognition of member achievements
-
Opportunities to connect with sponsors and industry partners
Agenda
5:15 – 6:15 pm
Reception and Networking
6:15 – 6:30 pm
Welcome from IAP President
Dr. Joseph Eaton, Iowa Pathology Associates
6:30 – 7:00 pm
Dinner
7:00 – 7:30 pm
Update from the College of American Pathologists
Bekra Yorke, MD
Vice-Chair, Federal and State Affairs Committee
College of American Pathologists
7:30 – 8:30 pm
Updates in the diagnosis and reporting of prostate cancer in needle biopsy
Gladell Paner, MD
Professor of Pathology and Surgery
University of Chicago Medical Center
8:30 pm
Thank You and Conclusion
Dr. Joseph Eaton, Iowa Pathology Associates
Location
The Graduate Hotel – Iowa City
210 S Dubuque St, Iowa City, IA 52240
Parking is available on-site and nearby public ramps.
Registration
Registration is now open. Please visit our event page for more information and to register for the evening.
CONTINUING EDUCATION CREDIT INFORMATION
Des Moines University Medicine and Health Sciences is the accredited provider and has approved this activity. If you have questions regarding continuing education credit, please email cme@dmu.edu.
Educational Grants: No ineligible company provided financial support for this continuing education activity.
Accreditation Statements:
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University Medicine and Health Sciences (DMU) and the Iowa Association of Pathologists. DMU designates this live activity for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University Medicine and Health Sciences (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 1.0 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Other healthcare providers: This activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
DISCLOSURES
The speaker(s) will disclose if any pharmaceuticals, medical procedures, or devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The activity director is responsible for determining educational content and selecting speakers.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Joseph Eaton, DO – Planning Committee Member
- Grace Fleming, CNP – Activity Director, Activity Coordinator, and Planning Committee Member
Relevant to the content of this educational activity, the following individual(s) have conflict(s) with ineligible companies to disclose. All relevant financial relationships have been mitigated through peer review by individuals with no relevant financial relationships or through attestation to evidence-based clinical guidelines.
Gladell Paner, MD, FCAP – Speaker
- Consultant: Ferring Pharmaceuticals, Johnson and Johnson
- The financial relationships have not ended; however, they are not relevant to the content of the education activity.
 |
 |
|
|
DISCLOSURES
The speaker(s) will disclose if any pharmaceuticals, medical procedures, or devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The activity director is responsible for determining educational content and selecting speakers.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Joseph Eaton, DO – Planning Committee Member
- Grace Fleming, CNP – Activity Director, Activity Coordinator, and Planning Committee Member
Relevant to the content of this educational activity, the following individual(s) have conflict(s) with ineligible companies to disclose. All relevant financial relationships have been mitigated through peer review by individuals with no relevant financial relationships or through attestation to evidence-based clinical guidelines.
Gladell Paner, MD, FCAP – Speaker
- Consultant: Ferring Pharmaceuticals, Johnson and Johnson
- The financial relationships have not ended; however, they are not relevant to the content of the education activity.